Over the past decade, there has been a philosophical switch within the neuropathology community from reliance on histology, a technique based on interpretation of classical dye-based stains such as H&E and immunohistochemistry with DAB-Hematoxylin observed in a brightfield microscope, to evaluation of genetic and molecular information in the cancer cells.  This transition required development of molecular pathology assays, and their incorporation into pathology has improved inter-observer reliability and neuro-oncology clinical decision-making.  However, over-reliance on molecular pathology has created other problems in resource poor settings globally and even in the United States.  Modern molecular pathology laboratories require expensive equipment and bioinformatics support. This physical and human resource infrastructure is not present in most developing countries, resulting in modern diagnostic services remaining out of reach to patients on a global scale.  Furthermore, American pathologists are constrained in most settings to only a few molecular assays due to insurance reimbursement issues.  It is therefore quite timely to write a book for the neuro-oncology community that would be a resource for pathologists, neuropathologists, neuro-radiologists, and radiation oncologists.  The book is separated into three parts.  The first part will review basic principles such as epidemiology and etiology and the background to the modern 2016 WHO classification of CNS tumors that was based on discoveries utilizing machine learning approaches to interpreting transcriptional and genomic data. It will also include chapters from neurosurgeons and oncologists discussing how these data are incorporated in working up a patient before and after the biopsy. Part I concludes with a general overview of common molecular techniques used in molecular pathology as well as a discussion of how to implement molecular pathology in a developing country.  Part II will focus on advances in patient stratification using molecular pathology, discuss key drivers of patient outcomes and predictors of response to radiation and/or chemotherapy treatment. A section focused on immunohistochemical surrogates for key molecular pathology findings will be included to aid resource-poor pathologists who may not have access to molecular assays. It will also close with a discussion of how oncologists integrate the molecular pathology for treatment plans. Part III concludes the work with reviews on radiomics, animal and stem cell models of glioblastoma, and a chapter on the emerging field of Glioblastoma Neuroscience.  The audience is intended for pathology residents and fellows interested in glioblastoma, general surgical pathologists who need reviews on how to implement modern glioblastoma classification, as well as neuro-radiologists, oncologists, and radiation oncologists needing a holistic perspective to glioblastoma diagnosis and management. The inclusion of chapters on how to implement molecular pathology in a developing country as well as current accepted immunohistochemical surrogate markers for key molecular pathology features will also broaden the appeal of the text. weiterlesen